Lance  Alstodt net worth and biography

Lance Alstodt Biography and Net Worth

Lance Alstodt has been appointed the Company’s President, Chief Executive Officer and Chairman of the Board as of Nov 16, 2020.  Mr. Alstodt brings over 25 years of experience in leading medical technology and lifesciences companies in operations, capital raising activities, strategy, and mergers and acquisitions.

Most recently, Mr. Alstodt was the Founder and CEO of MedVest Consulting Corporation (“MedVest”), an advisory and capital firm focused exclusively within the healthcare sector, focusing on growth and channel strategy, strategic planning, merger and acquisition support and investor activities.

Prior to MedVest, Mr. Alstodt was a career investment banker with over 25 years of experience in healthcare investment banking, including mergers and acquisitions. In 2011, Mr. Alstodt joined Leerink Partners as Managing Director to help lead its medical technology sector. Mr. Alstodt brings significant domain experience within the orthopedic and spine specific sectors. From 2008-2011, Mr. Alstodt was a Managing Director and Head of Medical Technology at Oppenheimer & Co. From 2000-2008, he was a Managing Director in the Healthcare Group and Global M&A Group at Bank of America Merrill Lynch (“BAML”). Prior to BAML, Mr. Alstodt spent seven years in the Global M&A Group at J.P. Morgan Chase, where he worked extensively on acquisitions, leveraged buyouts, private and public financings, exclusive sales and general advisory assignments.

Mr. Alstodt received a B.A. in Economics from the State University of New York at Albany, with a secondary concentration in Finance and Marketing.

What is Lance Alstodt's net worth?

The estimated net worth of Lance Alstodt is at least $280,467.40 as of September 15th, 2023. Mr. Alstodt owns 189,505 shares of BioRestorative Therapies stock worth more than $280,467 as of November 24th. This net worth evaluation does not reflect any other investments that Mr. Alstodt may own. Additionally, Mr. Alstodt receives a salary of $954,170.00 as CEO at BioRestorative Therapies. Learn More about Lance Alstodt's net worth.

How old is Lance Alstodt?

Mr. Alstodt is currently 53 years old. There are 3 older executives and no younger executives at BioRestorative Therapies. Learn More on Lance Alstodt's age.

What is Lance Alstodt's salary?

As the CEO of BioRestorative Therapies, Inc., Mr. Alstodt earns $954,170.00 per year. Learn More on Lance Alstodt's salary.

How do I contact Lance Alstodt?

The corporate mailing address for Mr. Alstodt and other BioRestorative Therapies executives is 40 MARCUS DRIVE, MELVILLE NY, 11747. BioRestorative Therapies can also be reached via phone at (631) 760-8100 and via email at [email protected]. Learn More on Lance Alstodt's contact information.

Has Lance Alstodt been buying or selling shares of BioRestorative Therapies?

Lance Alstodt has not been actively trading shares of BioRestorative Therapies during the past quarter. Most recently, on Tuesday, July 25th, Lance Alstodt bought 4,200 shares of BioRestorative Therapies stock. The stock was acquired at an average cost of $2.44 per share, with a total value of $10,248.00. Following the completion of the transaction, the chief executive officer now directly owns 184,418 shares of the company's stock, valued at $449,979.92. Learn More on Lance Alstodt's trading history.

Who are BioRestorative Therapies' active insiders?

BioRestorative Therapies' insider roster includes Lance Alstodt (CEO), and Francisco Silva (VP). Learn More on BioRestorative Therapies' active insiders.

Lance Alstodt Insider Trading History at BioRestorative Therapies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/25/2023Buy4,200$2.44$10,248.00184,418View SEC Filing Icon  
2/1/2023Buy400$3.10$1,240.00187,321View SEC Filing Icon  
1/27/2023Buy200$3.01$602.00186,921View SEC Filing Icon  
1/20/2023Buy200$3.13$626.00186,721View SEC Filing Icon  
1/18/2023Buy400$3.11$1,244.00186,521View SEC Filing Icon  
1/9/2023Buy100$3.08$308.00186,121View SEC Filing Icon  
12/23/2022Buy300$3.01$903.00186,021View SEC Filing Icon  
12/7/2022Buy1,800$2.99$5,382.00185,721View SEC Filing Icon  
11/18/2022Buy1,000$2.88$2,880.00183,921View SEC Filing Icon  
9/22/2022Buy200$2.92$584.00182,921View SEC Filing Icon  
7/12/2022Buy700$2.95$2,065.00182,721View SEC Filing Icon  
6/30/2022Buy1,100$3.10$3,410.00182,021View SEC Filing Icon  
6/15/2022Buy700$3.68$2,576.00180,321View SEC Filing Icon  
6/13/2022Buy200$3.95$790.00179,121View SEC Filing Icon  
6/8/2022Buy100$4.28$428.00178,921View SEC Filing Icon  
6/1/2022Buy200$4.60$920.00178,821View SEC Filing Icon  
5/26/2022Buy2,700$3.52$9,504.00178,621View SEC Filing Icon  
5/2/2022Buy400$3.95$1,580.00175,921View SEC Filing Icon  
1/24/2022Buy1,470$3.40$4,998.00View SEC Filing Icon  
1/5/2022Buy2,000$3.85$7,700.00View SEC Filing Icon  
12/1/2021Buy799$5.50$4,394.50View SEC Filing Icon  
11/22/2021Buy396$6.31$2,498.76View SEC Filing Icon  
11/16/2021Buy4,500$6.71$30,195.00View SEC Filing Icon  
9/9/2019Buy20,000$0.26$5,200.00
9/5/2019Buy10,000$0.27$2,700.00
8/27/2019Buy10,000$0.28$2,800.00View SEC Filing Icon  
8/21/2019Buy10,000$0.25$2,500.00View SEC Filing Icon  
See Full Table

Lance Alstodt Buying and Selling Activity at BioRestorative Therapies

This chart shows Lance Alstodt's buying and selling at BioRestorative Therapies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioRestorative Therapies Company Overview

BioRestorative Therapies logo
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.
Read More

Today's Range

Now: $1.48
Low: $1.40
High: $1.51

50 Day Range

MA: $1.62
Low: $1.38
High: $1.92

2 Week Range

Now: $1.48
Low: $1.03
High: $3.67

Volume

55,498 shs

Average Volume

749,185 shs

Market Capitalization

$10.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

63.4